Community Health Network

Ranked among the nation's most integrated healthcare systems, Community Health Network is Central Indiana's leader in providing convenient access to exceptional healthcare services, where and when patients need them—in hospitals, health pavilions, workplaces, schools and homes.

Explore Community

Close
News

News for Healthier Living

Zytiga's Use Expanded for Advanced Prostate Cancer

MONDAY, Dec. 10 (HealthDay News) -- U.S. Food and Drug Administration approval of Zytiga (abiraterone acetate) has been expanded to include treating late-stage castration-resistant prostate cancer before the administration of chemotherapy, the agency said Monday.

The drug, designed to decrease production of the male sex hormone testosterone, was first approved in November 2011. Testosterone is thought to spur the growth of prostate tumors, the FDA said in a news release.

Zytiga's approval for the new use followed a clinical study of 1,088 men with advanced, castration-resistant prostate cancer who hadn't received chemotherapy. Men who took Zytiga had a median survival of 35.3 months, compared to 30.1 months among those who took a placebo.

The most common adverse reactions included fatigue, swollen joints, hot flushes, diarrhea, vomiting, cough and high blood pressure.

Zytiga is marketed by Janssen Biotech, based in Horsham, Penn.

More information

To learn more about prostate cancer, visit the U.S. Centers for Disease Control and Prevention.

-- Scott Roberts

Copyright © 2012 HealthDay. All rights reserved.

Health Day

Proud sponsors

  • Indiana Fever
  • Indianapolis Indians
  • Indiana Pacers
  • Sarah Fisher Hartman Racing
  • Indy Eleven
  • Indy Fuel

Health and wellness shopping

  • Home Health Medical online store for medical supplies and equipment
  • Wellspring Pharmacy
  • FigLeaf Boutique
  • Jasmine gift shop